Current Overview of Treatment for Metastatic Bone Disease

Tsukamoto, Shinji; Kido, Akira; Tanaka, Yasuhito; Facchini, Giancarlo; Peta, Giuliano; Rossi, Giuseppe; Mavrogenis, Andreas F.

doi:10.3390/curroncol28050290

Cited by 84 publications

(74 citation statements)

References 192 publications

(303 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The management of bone metastases and haematological malignancy around the acetabulum remains a challenge. While some lesions can be managed nonoperatively, 14 larger, lytic, and symptomatic deposits that affect the structural integrity of the acetabulum merit surgery to alleviate pain, prevent fracture, and permit immediate weightbearing.…”

Section: Discussionmentioning

confidence: 99%

Survival of the GAP II cage in the management of metastatic disease of the acetabulum

Kennedy

Farhan-Alanie

Young

et al. 2022

The Bone & Joint Journal

View full text Add to dashboard Cite

Aims The aim of this study was to assess the clinical and radiological outcomes of an antiprotrusio acetabular cage (APC) when used in the surgical treatment of periacetabular bone metastases. Methods This retrospective cohort study using a prospectively collected database involved 56 patients who underwent acetabular reconstruction for periacetabular bone metastases or haematological malignancy using a single APC between January 2009 and 2020. The mean follow-up was 20 months (1 to 143). The primary outcome measure was implant survival. Postoperative radiographs were analyzed for loosening and failure. Patient and implant survival were assessed using a competing risk analysis. Secondary parameters included primary malignancy, oncological treatment, surgical factors, length of stay in hospital, and postoperative complications. Results A total of 33 patients (59%) died during the study period at a mean of 15 months postoperatively (1 to 63). No patient had radiological evidence of loosening or failure. Acetabular component survival was 100%. Three patients (5.4%) had further surgery; one (1.8%) underwent revision of the femoral component for dislocation, one required debridement with implant retention for periprosthetic joint infection, and one required closed reduction for dislocation. Using death as a competing risk, at 100 months, the probability of revision was 0.036 and the risk of death was 0.84. Conclusion With appropriate patient selection, the antiprotrusio cage offers good implant survival, with a reasonable perioperative complication rate in this high-risk group of patients when managing metastatic disease or haematological malignancy around the acetabulum. Cite this article: Bone Joint J 2022;104-B(4):504–509.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival of the GAP II cage in the management of metastatic disease of the acetabulum

Kennedy

Farhan-Alanie

Young

et al. 2022

The Bone & Joint Journal

View full text Add to dashboard Cite

show abstract

“…Prostate cancer often presents with BM, which are typically osteoblastic [ 105 ]. The process behind the development of osteoblastic metastases is still largely unknown but it seems to be related to the tumor production of osteoblastic factors, such as ET-1, growth differentiation factor 15, and bone morphogenic proteins [ 106 ].…”

Section: The Management Of Appendicular Impending and Pathologic Frac...mentioning

confidence: 99%

A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases

Brito

Lopes-Brás

Abrunhosa-Branquinho

et al. 2022

Cancers

View full text Add to dashboard Cite

Advances in medical and surgical treatment have played a major role in increasing the survival rates of cancer patients with metastatic bone disease. The clinical course of patients with bone metastases is often impaired by bone complications, such as bone fractures, which have a substantial negative impact on clinical outcomes. To optimize clinical results and prevent a detrimental impact on patients’ health, a tailored approach should be defined for any given patient. The optimal management of impending or pathologic fractures is unknown and relies on a multidisciplinary approach to tailor clinical decisions to each individual patient. The ability to control systemic disease, the extent, location and nature of bone metastases, and the biology of the underlying tumor, are the main factors that will define the strategy to follow. The present review covers the most recent data regarding impending and pathologic fractures in patients with bone metastases, and discusses the medical and surgical management of patients presenting with metastatic bone disease in different clinical settings.

show abstract

“…For example, PATHFx is a tool that utilizes patient specific data to generate survival probabilities at varying time points and has been validated in various populations internationally [27]. Other models have attempted to predict survival more accurately using sophisticated machine learning technology [28]. For example, Thio et al have developed a machine learning model which incorporates histology, metastases, previous therapy and a host of patient and laboratory factors.…”

Section: Prognosismentioning

confidence: 99%

The Surgical Management of Proximal Femoral Metastases: A Narrative Review

2021

View full text Add to dashboard Cite

The proximal femur is a common location for the development of bony metastatic disease. Metastatic bone disease in this location can cause debilitating pain, pathologic fractures, reduced quality of life, anemia or hypercalcemia. A thorough history, physical examination and preoperative investigations are required to ensure accurate diagnosis and prognosis. The goals of surgical management is to provide pain relief and return to function with a construct that provides stability to allow for immediate weightbearing. Current surgical treatment options include intramedullary nailing, hemiarthroplasty or total hip arthroplasty and endoprosthetic reconstructions. Oligometastatic renal cell carcinoma must be given special consideration as tumor resection and reconstruction has survival benefit. Both tumor and patient characteristics must be taken into account before deciding on the appropriate surgical intervention.

show abstract

Current Overview of Treatment for Metastatic Bone Disease

Cited by 84 publications

References 192 publications

Survival of the GAP II cage in the management of metastatic disease of the acetabulum

Survival of the GAP II cage in the management of metastatic disease of the acetabulum

A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases

The Surgical Management of Proximal Femoral Metastases: A Narrative Review

Contact Info

Product

Resources

About